WASHINGTON, DC (January 15, 2020) — The Association for Accessible Medicines and its Biosimilars Council applaud the decision by CMS to update the Part D program and allow plans to adopt a second, preferred specialty tier with lower cost-sharing. This proposal is an important first step to support adoption of biosimilars. It provides Part D plans another tool to contain drug costs for patients and taxpayers, and it will give plan formularies one more way to prefer and encourage use of lower cost specialty generics and biosimilars. We look forward to working with the new Administration and Congress to support plan adoption of new generics and biosimilars through comprehensive Part D reform.
MEDIA CONTACT:
Rachel Schwartz
202.249.7147
About AAM
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.